Figures computed from official regulatory filings — .
Ownershipinsiders 0.51% · institutions 0.52%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BIOPHYTIS only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
Market information source · Oct 19, 2026
Open-market timeline · full history
1 buy5 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| STANISLAS VEILLET | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| STANISLAS VEILLET | Sell | $608.6K | AMF |
| STANISLAS VEILLET | Sell | $452.1K | AMF |
| STANISLAS VEILLET | ExerciseD (derivative) | $496.6K | AMF |
| STANISLAS VEILLET | AwardD (derivative) | $194.6K | AMF |
| STANISLAS VEILLET | ExerciseD (derivative) | $193.6K | AMF |
| STANISLAS VEILLET | BuyD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | First in 12mo | AMF |
| STANISLAS VEILLET | Buy | $86.4K | conv 87First in 12mo | AMF |
| STANISLAS VEILLET | Sell | $634.3K | AMF |
| STANISLAS VEILLET | Sell | $488.5K | AMF |
| STANISLAS VEILLET | ExerciseD (derivative) | $199.4K | AMF |
| EVELYNE NGUYEN | Sell | $63.9K | AMF |
| EVELYNE NGUYEN | Exercise | $24.6K | AMF |
| DIMITRI BATSIS | SellD (derivative) | $34.9K | AMF |